SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A-1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
JULY 19, 2004
GenoMed, INC.
------------
(Exact name of registrant as specified in its charter)
FLORIDA 000-49720 43-1916702
---------------------------- ---------------- ----------------------
(State or other jurisdiction (Commission file (IRS Employer
of incorporation) number) Identification Number)
9666 Olive Blvd., Suite 310, St. Louis, Missouri 63132
----------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
----------------------------------------------------------
(314) 652-0500
909 South Taylor Avenue, St. Louis, Missouri 63110
--------------------------------------------------------
(Former name or former address if changed since last report)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
(b) Effective July 19, 2004, we have engaged Rubin, Brown, Gornstein & Co., LLP
("RBG") of St. Louis, Missouri, to serve as our independent accountant to audit
our financial statements.
During our two most recent fiscal years and the period from January 1, 2004 to
the date we engaged RBG, we did not consult RBG regarding the application of
accounting principles to a specific completed or contemplated transaction or the
type of audit opinion that might be rendered on our financial statements, and no
written or oral advice was provided by RBG during that period on any such issue
that was a factor considered by us in reaching a decision as to any accounting,
auditing or financial reporting issue. During that period, we did not consult
RBG on any matter that was either the subject of a disagreement or a reportable
event with regard to our prior auditors.
We have provided a copy of the disclosure in this report to RBG and offered RBG
the opportunity to furnish a letter to the Commission contemplated by Item
304(a)(2)(D) of Regulation S-B. RBG has advised us that it does not intend to
furnish such letter to the Commission.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amended report to be signed on its behalf by the
undersigned hereunto duly authorized.
GenoMed, Inc.
Dated: July 27, 2004 By: /s/ David Moskowitz
------------------------------
Dr. David Moskowitz
Chairman of the Board and
Chief Executive Officer